Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer

Abstract The androgen receptor signaling inhibitor enzalutamide (Enz) is one the primary therapeutic drugs for advanced prostate cancer (PCa). Nevertheless, most of patients ultimately develop resistance to Enz. Through an integrated analysis of CRISPR genome-wide and kinome-wide screens, coupled wi...

Full description

Bibliographic Details

Published in:	Biomarker Research
Main Authors:	Fu-Hao Ji, Yu-Hang Qian, Xiu-Chen Guo, Hai-Hong Liao, Jia-Cheng Huang, Zi-Han Xu, Ming-Ming Yu, Yan-Yuan Wu, Jie-Wen Bao, Hao-Jie Chen, Yong-Jiang Yu, Lin Wang
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Prostate cancer Enzalutamide RPS6KC1 scRNA-seq
Online Access:	https://doi.org/10.1186/s40364-025-00822-x